Osentia has been developed by Crescent, a UK company

Osentia uses Crescent's patented osteoporosis screening process. The test identifies the risk of fragility fracture using a nail clipping by analysing the protein structure of the nail.

Dr Towler discovered using Raman spectroscopy that the structure of the protein keratin in nails differed from patients with healthy bones and those with fragile bones. This suggests a link between the structure of keratin and bone health.

Crescent conducted a series of clinical trials in which keratin was analysed using Raman spectroscopy and nail donors and medical histories were followed in relationship to fragility fractures. These trials established a link between the structure of keratin in a nail and a risk of an individual developing a fragility fracture.

Now for the first time consumers will be able to access this technology via Osentia.